Therefore, prolonged daily ATRi treatment for 9 consecutive days reduces activated CD8+ T cell populations (Tem and Tcm) and abolishes the expansion of both CD8+ Tem and tumor antigen–specific CD8+ T cells in the DLN at day 9, one week after RT. The gene discussed is CD8A; the disease is neoplasm.